Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

802 Risultati di ricerca.

NSCH 2016 Children Ages 12-17 - B. This Child as an Infant

- 2021-09-20 - 11 moduli, 1 ItemGroup, 3 elementi, 1 linguaggio

ItemGroup: Infant

Study part: Children Ages 12-17 National Survey of Childrens Health, NSCH, 2016. A study by the U.S. Department of Health and Human Services to better understand the health issues faced by children in the United States today. Child and Adolescent Health Measurement Initiative, Data Resource Center on Child and Adolescent Health website. Retrieved on 07/12/2016 from http://childhealthdata.org/learn/NSCH/resources/survey-instruments. OMB No. 0607-0990: Approval Expires 04/30/2019.

A. This Child’s Health

1 ItemGroup 108 elementi

D. Experience with This Child’s Health Care Providers

1 ItemGroup 30 elementi

E. This Child’s Health Insurance Coverage

1 ItemGroup 18 elementi

F. Providing for This Child’s Health

1 ItemGroup 8 elementi

I. About Your Family and Household

1 ItemGroup 34 elementi

K. Household Information

1 ItemGroup 15 elementi

Mostra di più

NSCH 2016 Children Ages 0-5 - B. This Child as an Infant

- 2021-09-20 - 11 moduli, 1 ItemGroup, 10 elementi, 1 linguaggio

ItemGroup: Infant

Study part: Children Ages 0-5 National Survey of Childrens Health, NSCH, 2016. A study by the U.S. Department of Health and Human Services to better understand the health issues faced by children in the United States today. Child and Adolescent Health Measurement Initiative, Data Resource Center on Child and Adolescent Health website. Retrieved on 07/12/2016 from http://childhealthdata.org/learn/NSCH/resources/survey-instruments. OMB No. 0607-0990: Approval Expires 04/30/2019.

D. Experience with This Child’s Health Care Providers

1 ItemGroup 18 elementi

F. Providing for This Child’s Health

1 ItemGroup 8 elementi

E. This Child’s Health Insurance Coverage

1 ItemGroup 18 elementi

C. Health Care Services

1 ItemGroup 49 elementi

A. This Child’s Health

1 ItemGroup 99 elementi

I. About Your Family and Household

1 ItemGroup 32 elementi

Mostra di più

NSCH 2016 Children Ages 6-11 - B. This Child as an Infant

- 2021-09-20 - 11 moduli, 1 ItemGroup, 3 elementi, 1 linguaggio

ItemGroup: Infant

Study part: Children Ages 6-11 National Survey of Childrens Health, NSCH, 2016. A study by the U.S. Department of Health and Human Services to better understand the health issues faced by children in the United States today. Child and Adolescent Health Measurement Initiative, Data Resource Center on Child and Adolescent Health website. Retrieved on 07/12/2016 from http://childhealthdata.org/learn/NSCH/resources/survey-instruments. OMB No. 0607-0990: Approval Expires 04/30/2019.

F. Providing for This Child’s Health

1 ItemGroup 8 elementi

E. This Child’s Health Insurance Coverage

1 ItemGroup 18 elementi

I. About Your Family and Household

1 ItemGroup 34 elementi

K. Household Information

1 ItemGroup 15 elementi

G. This Child’s Learning

1 ItemGroup 11 elementi

H. About You and This Child

1 ItemGroup 21 elementi

Mostra di più

Ministry of Health, Ethiopia- HIV–Exposed Infant Follow up Card - HIV–Exposed Infant Follow up Card

- 2016-07-05 - 1 modulo, 2 itemgroups, 52 elementi, 1 linguaggio

Itemgroups: Demographics, Follow up chart

Form provided by Binyam Tilahun. Source: http://www.moh.gov.et/ (Ministry of Health, Ethiopia)

Ministry of Health, Ethiopia- HMIS HIV exposed infant logbook card - HIV exposed infant logbook card

- 2016-07-06 - 1 modulo, 1 ItemGroup, 27 elementi, 1 linguaggio

ItemGroup: Logbook card

Form provided by Binyam Tilahun. Source: http://www.moh.gov.et/ (Ministry of Health, Ethiopia)

dbGaP phs001201 ASsessing and Predicting Infant RSV Effects and Severity (AsPIRES) Study - pht007555.v2.p1

- 2023-05-24 - 9 moduli, 1 ItemGroup, 2 elementi, 1 linguaggio

ItemGroup: pht007555

Principal Investigator: Edward E. Walsh, M.D, University of Rochester Medical Center, Rochester, NY, USA MeSH: Respiratory Syncytial Virus Infections,Infant https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001201 A prospective multi-year clinical translational study including three cohorts of term infants experiencing their first Respiratory Syncytial Virus (RSV) season. All infants are less than or equal to nine months of age at study entry. The three subject cohorts represent the full spectrum of RSV disease severity and include a birth cohort, a cohort of infants hospitalized for RSV disease and infants evaluated at ambulatory settings for RSV infection. All infants are followed longitudinally and evaluated at recognition of acute RSV infection and twice during convalescence. Innate and adaptive immune status are comprehensively measured in association with clinical, environmental, viral, and bacteriologic factors. Genome-wide expression is assessed in the nasal airways, and in sorted peripheral blood lymphocytes. The study goal is to Identify host responses to RSV infection and factors associated with severe disease.

pht007556.v1.p1

1 ItemGroup 3 elementi

pht007557.v2.p1

1 ItemGroup 13 elementi

pht007558.v1.p1

1 ItemGroup 9 elementi

pht007559.v1.p1

1 ItemGroup 20 elementi

pht007560.v2.p1

1 ItemGroup 66 elementi

pht008325.v1.p1

1 ItemGroup 18 elementi

Mostra di più

Neurology follow Pediatric surgery UKM - Neurology follow up

- 2016-12-12 - 1 modulo, 2 itemgroups, 9 elementi, 2 lingue

Itemgroups: Patient identification, Neurological assessment

Neurology follow up form converted to ODM format. Routine documentation of University Hospital of Münster.

dbGaP phs000490 A Study of the Genetic Causes of Complex Pediatric Disorders - pht002969.v1.p1

- 2022-11-04 - 10 moduli, 1 ItemGroup, 32 elementi, 1 linguaggio

ItemGroup: pht002969

Principal Investigator: Hakon Hakonarson, MD, PhD, Center for Applied Genomics, Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA MeSH: Asthma,Attention Deficit Disorder with Hyperactivity,Dermatitis, Atopic,Gastroesophageal Reflux,Lipoproteins, LDL https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000490 The Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia (CHOP) is a high-throughput, highly automated genotyping and sequencing facility equipped with state-of-the-art genotyping and sequencing platforms. Children who are treated at the Children's Hospital Healthcare Network and their parents may be eligible to take part in a major initiative to collect more than 100,000 blood samples, covering a wide range of pediatric diseases. A large majority of participants consenting to prospective genomic analyses also consent to analysis of their de-identified electronic medical records (EMRs). EMRs are longitudinal, with a mean duration of 6.5 years. CAG has committed to releasing genotype and phenotype data for 4000 individuals diagnosed with *asthma*, *ADHD*, *atopic dermatitis*, *GERD* (1000 for each), and 1000 individuals on the upper and lower ranges of *Low-Density Lipoprotein* (LDL) levels to dbGaP. We will also release genotype/phenotype of 3000 controls. Relevant phenotype data includes primary diagnoses (ICD9 codes), secondary diagnoses (ICD9 codes), medical procedures/tests conducted in relation to the phenotype, and a listing of relevant medications. Further details of CAG's research programs and capacity are available at: http://www.caglab.org

pht002961.v1.p1

1 ItemGroup 3 elementi

pht002963.v1.p1

1 ItemGroup 3 elementi

pht002964.v1.p1

1 ItemGroup 21 elementi

pht002965.v1.p1

1 ItemGroup 27 elementi

pht002966.v1.p1

1 ItemGroup 26 elementi

pht002967.v1.p1

1 ItemGroup 28 elementi

Mostra di più

Effects of eltrombopag in children with chronic idiopathic thrombocytopenic purpura, NCT00908037 - Demography

- 2019-10-16 - 1 modulo, 4 itemgroups, 15 elementi, 1 linguaggio

Itemgroups: Administrative Data, Demography, Ethnicity, Geographic ancestry

Study ID: 108062 Clinical Study ID: 108062 Study Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00908037 https://clinicaltrials.gov/ct2/show/NCT00908037 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: eltrombopag, Placebo Trade Name: N/A Study Indication: Purpura, Thrombocytopaenic, Idiopathic The study consists of a screening, Day 1 and three parts. All subjects were supposed to receive 24 weeks (6 months) of eltrombopag treatment during Part 2/3. Screening period: Up to 28 days prior to Day 1 of treatment. Day 1 Part 1 (Dose Finding Phase): A 24-week (6 months) open label treatment period for 5 subjects in each age cohort. (short: P1W1-P1W7, P1W8-23, P1W24/EW). A safety, PK and platelet count review took place after 12 weeks (3 months) of treatment. Subjects in the Dose Finding Phase did not participate in the Randomized Period. Part 2 (Randomized Period): A 7-week randomized, double-blind, placebo-controlled period involving 18 subjects per cohort (short: P2W1-P2W7). Part 3: An open-label treatment period where subjects randomized to eltrombopag in Part 2 received an additional 17 weeks of eltrombopag in Part 3 and subjects randomized to placebo in Part 2 received 24 weeks of eltrombopag in Part 3 (short: P3W8-P3W23, P3W24/EW, P3W8-30, P3W31/EW). Follow-up: 4 weeks following the last dose of eltrombopag (short: FUW1- FUW4). Additional ocular examinations were performed at 12 and 24 weeks (3 and 6 months) after the last dose of eltrombopag (short: FUM3, FUM6). The subjects were enrolled in 3 cohorts: Cohort 1: Subjects between 12 and 17 years old (<18 years of age at Day 1). Cohort 2: Subjects between 6 and 11 years old (<12 years of age at Day 1). Cohort 3: Subjects between 1 and 5 years old (<6 years of age at Day 1). The enrollment was started with the oldest cohort (Cohort 1). The younger cohorts were not enrolled until safety, PK and platelet counts had been reviewed in the older cohort(s). This document contains the demography form. It has to be filled in for screening.

Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858 - Study Completion

- 2020-09-14 - 1 modulo, 5 itemgroups, 25 elementi, 1 linguaggio

Itemgroups: Administrative Data, Completion of study by subject, Study completed by subject, Study not completed by subject, Investigator's Signature

Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form is to be completed on Study Conclusion and is used to verify that no important steps were omitted. Also includes Investigator's Signature.

Calcium Intake - Children PhenX Toolkit

- 2016-04-26 - 1 modulo, 1 ItemGroup, 21 elementi, 1 linguaggio

ItemGroup: PhenX - calcium intake - pediatric protocol

These self-administered questions are for use with children of middle school-age (aged 11-14 years). Each question has a multichoice answer. Pictures help guide the children’s responses to the questions. ODM derived from: https://cde.nlm.nih.gov Primary source: https://www.phenxtoolkit.org/ Recent publication: Hendershot, T., Pan, H., Haines, J., Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M., and Hamilton, C.M. (2015) Using the PhenX toolkit to add standard measures to a study. Curr. Protoc. Hum. Genet. 86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86 Permission to publish granted by Carol M. Hamilton.

Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858 - 30-Day Followup (+/- 14 Days)

- 2020-10-24 - 1 modulo, 5 itemgroups, 32 elementi, 1 linguaggio

Itemgroups: Administrative Data, Followup visit, Vital Signs, Physical examination, Clinical Endpoints

Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form has to be filled in at the Followup Visit. It records Vital Signs, changes from the Post-Treatment Exam and (re)occurence of specified Events.

Keywords

Sommario

Modelli di dati selezionati

Contatto

Aiuto